Presence of circulating antinuclear antibodies (ANAs) in patient serum is widely regarded as the hallmark of systemic
autoimmune rheumatic disease . A request for a serological
ANA screening test is usually a first step for the laboratory diagnosis
Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among antinuclear antibodies (ANA) positive healthy individuals (HI). We assessed the prevalence of anti-DFS70 antibodies in patients with and without ANA-associated rheumatic diseases (AARDs) by two methods: chemiluminescent immunoassay (CIA) and an indirect immunofluorescence (IIF) assay based on immunoadsorption for DFS70.
Antinuclear antibodies: Is the indirect immunofluorescence still the gold standard or should be replaced by solid phase assays?
Antinuclear antibodies (ANA) are important biomarkers for systemic lupus erythematosus (SLE) and represent a criterion for patient classification. While ANAs are not specific for SLE, patients with SLE are thought to be almost invariably positive.